Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study from interferon beta-1a or glatiramer acetate to natalizumab in relapsing-remitting multiple sclerosis
2009-015556-15Phase 3Terminated
- Sponsor
- Biogen
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Biogen. Primary endpoint: Annualized relapse rate. Started Feb 2010; status: terminated.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2009-015556-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015556-15.